

Appendix A

Claim Amendments

1. (Currently amended) ~~Method~~ A method of treatment or prophylaxis of diseases associated with or based on impairment or dysfunction of cerebral vascular reactivity in a patient afflicted with such disease comprising the step of administering a pharmacologically tolerable and therapeutically effective amount of a PDE5 inhibitor to the patient in need thereof.
2. (Currently amended) ~~Method~~ The method of treatment according to claim 1 wherein the disease is associated with pre-senile dementia.
3. (Currently amended) ~~Method~~ The method of treatment according to claim 1 [[or 2]], wherein the disease is selected from the group consisting of vascular-dementia, ~~and/or~~ neuronal dementia, diabetes associated impairments of neurovascular-coupling, impairments of cerebral vascular function secondary to systemic arterial hypertension, ~~and/or~~ impairments of

cerebral vascular function secondary to
arteriosclerosis, Alzheimer's disease, Parkinson
disease and Huntington's disease.

4. (Currently amended) ~~Method~~ The method of treatment
according to claim 1, wherein the disease is
associated with or based on post-ischemic disturbances
of cerebral function.

5. (Currently amended) ~~Method~~ The method according to
claim 1 ~~[[or 4]]~~, wherein the disease is based on
cerebral insults, stenosis of extra- or intra-cerebral
arteries or cerebral bleeding.

6. (Currently amended) ~~Method~~ The method according to
claim 1, wherein the disease ~~diseases~~ is associated
with impairments of cognitive function associated
microcirculatory disorders/dysfunction.

7. (Currently amended) ~~Method~~ The method according to
claim 1 ~~[[or 6]]~~, wherein the disease is selected from
the group consisting of septic encephalopathy,
arteriosclerotic encephalopathy, diabetes associated

encephalopathy, toxic encephalopathy, multiple sclerosis, Creutzfeldt-Jakob disease, encephalopathy associated with autoimmune thyroiditis (Hashimoto's encephalitis), autoimmune thyroiditis, cerebral microangiopathy), hypercholesterolemia, hypertriglyceridemia, hypertension, pulmonary hypertension, peripheral arterial disease, chronic renal failure, chronic heart failure, sepsis, preeclampsia [[,]] and celiac disease.

8. (Currently amended) ~~Method~~ The method according to claim 1, [[6 or 7,]] wherein the disease is sepsis associated encephalopathy (SAE).

9. (Currently amended) ~~Method~~ The method according to ~~any of the preceding claims~~ claim 1, wherein the PDE 5 inhibitor is selected from the group consisting of sildenafil, vardenafil and tadalafil.

10. (Currently amended) ~~Method~~ The method of treatment or prophylaxis of any of the diseases as indicated in claim 2 ~~any of the claims 2 to 7~~ in a patient afflicted with such disease comprising the

step of administering a pharmaceutically tolerable and therapeutically effective amount of a compound capable to improve cerebral vascular reactivity and to influence kinetic adaptation of cerebral blood flow.

11. - 20. (Canceled)